PfCRT and its role in antimalarial drug resistance

Andrea Ecker, Adele M. Lehane, Jérôme Clain, David A. Fidock*

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    221 Citations (Scopus)

    Abstract

    Plasmodium falciparum resistance to chloroquine, the former gold standard antimalarial drug, is mediated primarily by mutant forms of the chloroquine resistance transporter (PfCRT). These mutations impart upon PfCRT the ability to efflux chloroquine from the intracellular digestive vacuole, the site of drug action. Recent studies reveal that PfCRT variants can also affect parasite fitness, protect immature gametocytes against chloroquine action, and alter P. falciparum susceptibility to current first-line therapies. These results highlight the need to be vigilant in screening for the appearance of novel pfcrt alleles that could contribute to new multi-drug resistance phenotypes.

    Original languageEnglish
    Pages (from-to)504-514
    Number of pages11
    JournalTrends in Parasitology
    Volume28
    Issue number11
    DOIs
    Publication statusPublished - Nov 2012

    Fingerprint

    Dive into the research topics of 'PfCRT and its role in antimalarial drug resistance'. Together they form a unique fingerprint.

    Cite this